Glucose-lowering effect of insulin glargine 300 U/ml in Japanese type 2 diabetic patients treated with basal-bolus insulin therapy

Glucose-lowering effect of insulin glargine 300 U/ml in Japanese type 2 diabetic patients treated with basal-bolus insulin therapy - Glucose-lowering effect of insulin glargine 300 U/ml in Japanese type 2 diabetic patients treated with basal-bolus insulin therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019352

Enrollment

Registered

2015-10-14

Start date

2015-10-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

Injecting insulin glargine 300 U/ml once daily until 5 weeks after insulin dosage is fixed.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - adults with type 2 diabetes mellitus - treated with basal-bolus insulin therapy - living a well-regulated life - time interval between breakfast and lunch, lunch and dinner, and dinner and breakfast was 6, 6, and 12 hours, respectively, with a tolerance of +/- 3 hours

Exclusion criteria

Exclusion criteria: - treated with antidiabetic drugs other than insulin - difficulty to perform self-monitoring of blood glucose - severe hepatic, renal and/or cardiac disease - hypersensitivity to insulin glargine 300 U/ml - pregnant or breast-feeding females. - Patients who are judged by the investigator to be inappropriate for this study for any other reason.

Design outcomes

Primary

Measure	Time frame
Daily profiles of glucose levels after injection of insulin glargine 300 U/ml	—

Countries

Japan

Contacts

Public ContactToshihiko Shiraiwa

Shiraiwa Medical Clinic Shiraiwa Medical Clinic

shiraiwa@endmet.med.osaka-u.ac.jp072-971-1221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026